Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
This bill (Mikaela Naylon Give Kids a Chance Act of 2025) amends the Federal Food, Drug, and Cosmetic Act to create specific authorities and requirements for “molecularly targeted pediatric cancer investigations” tied to certain new drug or biological applications, including when the product will be studied in combination with other drugs that are standard of care or hit relevant molecular targets.
It requires those pediatric investigations to be designed to produce clinically meaningful pediatric dosing, safety, and preliminary efficacy data using age-appropriate formulations, limits when combination investigations may be required, and directs the FDA to issue guidance within specified timeframes.
The bill delays applicability of the amendments until three years after enactment, requires periodic reports to Congress and GAO studies on effectiveness, and extends the rare pediatric disease priority review voucher (PRV) authority through September 30, 2030 while changing when the PRV user fee is due and mandating a GAO study of voucher effectiveness.
The bill is a relatively narrow, technical set of amendments aimed at improving pediatric cancer drug development and maintaining an industry incentive; such measures often receive bipartisan interest. Its moderate regulatory impact, delayed effective date, and built-in evaluation measures improve acceptability. Remaining obstacles include possible industry pushback over new study requirements or FDA resource implications, absence of a cost estimate in the text, and the usual legislative competition for calendar and amendment tradeoffs.
Relative to its intended legislative type, this bill is a well-specified statutory amendment package that integrates directly into existing FD&C Act provisions, prescribes investigational-design expectations, sets implementation timelines for guidance, delays applicability to allow transition, and requires follow-up reporting and GAO studies. It provides clearer-than-average legal mechanics and oversight for a substantive policy change.
Scope and acceptability of increased FDA authority: liberals generally accept more agency action to require pediatric data, conservatives view this as regulatory overreach.
Scope and acceptability of increased FDA authority: liberals generally accept more agency action to require pediatric data, conservatives view this as regulatory overreach.
A mainstream liberal view would likely be broadly positive about the bill’s aim to increase deliberate pediatric cancer study requirements and produce age‑appropriate data to inform pediatric labeling.
Supporters would note the targeted approach for molecularly relevant drugs and the requirement for clinically meaningful pediatric data and formulations as important protections for children.
They may be cautious about the extension and mechanics of priority review vouchers, wanting assurance the voucher program actually incentivizes pediatric treatments rather than simply rewarding companies without improving access or affordability.
A pragmatic, moderate view would see the bill as a largely defensible, targeted reform to close gaps in pediatric cancer evidence while balancing industry feasibility with public health.
The centrist would appreciate the specificity (molecular targeting, limitations on combination requirements), the delayed applicability to allow adjustments, and the requirement for guidance and independent GAO studies.
They would also be attentive to tradeoffs: potential regulatory burdens on developers, how the PRV extension affects FDA throughput and priorities, and fiscal or timing impacts that are not fully specified in the bill.
A mainstream conservative perspective would be skeptical of expanding FDA authority to require pediatric investigations, particularly for drug combinations, viewing it as added regulatory burden that may slow or deter drug development.
While the PRV extension could be seen as a market incentive consistent with private‑sector solutions, conservatives would likely object to additional mandates without clear evidence they produce net public benefit and may object to potential impacts on innovation costs.
They would favor tighter limits on FDA discretion, clearer cost limits, and protections for industry from open‑ended requirements.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
The bill is a relatively narrow, technical set of amendments aimed at improving pediatric cancer drug development and maintaining an industry incentive; such measures often receive bipartisan interest. Its moderate regulatory impact, delayed effective date, and built-in evaluation measures improve acceptability. Remaining obstacles include possible industry pushback over new study requirements or FDA resource implications, absence of a cost estimate in the text, and the usual legislative competition for calendar and amendment tradeoffs.
The bill has not accumulated any surfaced votes yet.
Scope and acceptability of increased FDA authority: liberals generally accept more agency action to require pediatric data, conservatives v…
The bill is a relatively narrow, technical set of amendments aimed at improving pediatric cancer drug development and maintaining an indust…
Relative to its intended legislative type, this bill is a well-specified statutory amendment package that integrates directly into existing FD&C Act provisions, prescribes investigational-design expectations, sets imple…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.